Menu

Recent Interviews

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CAN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


30. June 2021 | 12:59 CET

CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!

  • Biotechnology
Photo credits: pixabay.com

Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?

time to read: 3 minutes by Carsten Mainitz
ISIN: CUREVAC N.V. O.N. | NL0015436031 , CARDIOL THERAPEUTICS | CA14161Y2006 , MORPHOSYS AG O.N. | DE0006632003


 

Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author


CUREVAC NV - The countdown is on

In mid-June, German biotech Company CureVac provided information on its first-generation Corona vaccine candidate, announcing that a preliminary evaluation showed the compound had an efficacy of around 47%. This announcement hit like a bomb. As a result, the share price fell by half. In the meantime, the shares have recovered somewhat to around EUR 54.

The sharp drop was due to the significantly lower efficacy of the vaccine compared to competitors' preparations. In addition, the vaccine has not yet been approved. Astra Zeneca, BioNTech/Pfizer, Moderna and Johnson & Johnson are currently dividing the cake among themselves. Those who are too late may only have a few crumbs left.

Now the CEO of the Tübingen-based vaccine developer CureVac, Franz-Werner Haas, has spoken out. Haas expects final results from the pivotal study phase very soon. "It won't take more than a week or ten days. We expect the results in the short term," Haas said Monday at a press conference. Like BioNTech and Moderna, CureVac relies on mRNA technology. However, the Tübingen-based Company is pursuing a slightly different approach. Haas remained convinced that the vaccine could be approved. Amsterdam's European Medicines Agency (EMA) initiated a rapid review process for the Tübingen-based Company's vaccine in February. The federal government also has a vested interest in the South German Company's success for two reasons. First, because the vaccine is firmly scheduled for a later vaccination campaign, and second, the federal government has invested EUR 300 million in CureVac through Aufbaubank KfW and holds a 16% stake.

CARDIOL THERAPEUTICS INC - When will the revaluation start?

Cardiol Therapeutics is breaking new ground in inflammatory heart disease therapy. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that suggests the use of cannabidiol as an anti-inflammatory agent is beneficial. The Company has an exclusive manufacturing agreement for a pharmaceutical cannabidiol formulation that is highly concentrated and THC-free. In April, Cardiol enrolled the first patients in LANCER for a Phase II/III outcomes study in high-risk patients treated with Covid-19. The single and multiple ascending dose Phase I clinical trial showed successful topline results for CardiolRx in April. The Company filed for listing on NASDAQ in March 2021. Trading on the NASDAQ is expected to result in a significant valuation boost for the stock.

Characteristically, companies like Cardiol operate at a loss in the early stages. The potential of the existing product pipeline and the management team's expertise enabled the Company to raise more than CAD 50 million on the capital market in the last 12 months. That is a considerable house number. The analysts of GBC certify the Company in the case of success, enormous profits, and formulate a price target of CAD 15.77 - a potential fivefold! In addition, the analysts classify the Company as a takeover target in case of positive results of the Covid-19 phase II/III trials. Currently, the shares are trading around CAD 3, giving the Company a market capitalization of CAD 127 million.

MORPHOSYS AG - Now?!

In recent months, the MorphoSys share has only known reverse gear. While the shares were still quoted at EUR 120 last summer, only EUR 68 per share is called up. The Company is thus valued at EUR 2.2 billion. The acquisition of NASDAQ-listed Constellation Pharmaceuticals Inc. for USD 34 per share in cash, announced in June, failed to give the share price any positive impetus. Analysts see clear upside potential for the German stock, but that is not helping at the moment. Perhaps a cancer drug that the US pharmaceutical Company Incyte is marketing together with MorphoSys will soon revive the share price. Incyte has concrete hopes of obtaining approval for its blood cancer drug tafasitamab in Europe. As reported last Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive recommendation for the drug. If marketing is then made possible in the next step, this should be reflected in rising share prices.


Author

Carsten Mainitz

The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read